UNSPSC 51373446: Codeine/ipecac/potassium guaiacolsulfonate/promethazine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373446 Codeine/ipecac/potassium guaiacolsulfonate/promethazine is a Commodity code that in recent state and local procurement activity encompasses naloxone, drug deactivation systems, and multi-source generic pharmaceuticals distributed through authorized wholesalers to government health and social-service facilities. The issuing bodies soliciting under this code span county health departments, state procurement offices administering cooperative purchasing alliances, and multi-state purchasing consortia. Seminole County, Florida procures naloxone and drug deactivation systems as components of community health initiatives; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, establishes master contracts for generic pharmaceuticals and OTC products available to participating state and local government entities across multiple states including Oregon. Both opportunities reflect demand for pharmaceutical supply-chain contracting that pairs direct-purchase models (county-level procurement) with wholesaler-mediated distribution networks (cooperative purchasing).

Recent activity concentrates in Florida and the upper Midwest. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: source dates suggest a potential data inconsistency), with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida and vendor responsibility for shipping costs. MMCAP issued RFP S1070000015802 on January 20, 2026, due March 26, 2026, to establish multiple awards for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and the remainder on compliance and EDI capability; products must be available by May 15, 2026 and agreements effective July 1, 2026. Neither opportunity discloses explicit budget ranges or set-aside designations.